Cookies help us deliver our services. By using our services, you agree to our use of cookies. Click here to learn more

Affymax Reviews

3.9
9 Reviews
Rating Trends
Recommend to a friend
Approve of CEO
Affymax CEO and Director John Orwin
John Orwin
1 Rating

Affymax Interviews

Updated 14 Mar 2015
Updated 14 Mar 2015

Interview Experience

Interview Experience

25%
25%
50%

Getting an Interview

Getting an Interview

44%
27%
27%

Interview Difficulty

2.2
Average

Interview Difficulty

Hard

Average

Easy
  1.  

    Intern Interview

    Anonymous Interview Candidate
    Anonymous Interview Candidate
    Application Details

    I applied through college or university. The process took 2 weeksinterviewed at Affymax.

    Interview Details

    it was straight forward. Telephonic was followed by a team interbiew of 2 scientists and 2 associates. They asked general interview questions such as why this company, Your future plan, how did u hear about us. What interests you? How are your chemistry lab skills. How are you with large programmable lab instruments.

    Interview Questions
    • Instrumentation, chromatography, it's phases, types etc   Answer Question
    Accepted Offer
    Positive Experience
    Average Interview

Affymax Awards and Accolades

Let us know if we're missing any workplace or industry recognition – Add an award

Additional Info

Unlock Profile
Website www.affymax.com
Headquarters Palo Alto, CA
Size 16 to 50 Employees
Founded 2001
Type Company - Public
Industry Biotech & Pharmaceuticals
Revenue £1 to £5 million (GBP) per year
Competitors Amgen, Janssen Biotech, Roche

Affymax is designing peptides to give red blood cells a pep talk. The biotechnology firm is researching and developing possible drugs based upon these biological process regulators. Its leading drug candidate, Hematide, is an erythropoietin (EPO) mimetic, designed to stimulate red blood cell production, like EPO itself. Hematide is being investigated in late stage clinical trials as a possible treatment for anemia caused by chronic renal failure and chemotherapy. Affymax believes Hematide will be cheaper and longer lasting than the EPO stimulants currently used on dialysis... More

Work at Affymax? Share Your Experiences

Affymax

 
Click to Rate
or